Use of non-formulary high-cost medicines in an Australian public hospital

[1]  R. Moots,et al.  Biosimilars: From Extrapolation into Off Label Use. , 2018, Current pharmaceutical design.

[2]  G. Schumock,et al.  National trends in prescription drug expenditures and projections for 2017. , 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  J. Bosch,et al.  Outcomes of off-label drug uses in hospitals: a multicentric prospective study , 2014, European Journal of Clinical Pharmacology.

[4]  P. Pillans,et al.  Experience with low‐dose rituximab in off‐label indications at two tertiary hospitals , 2013, Internal medicine journal.

[5]  P. Jolliet,et al.  Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? , 2013, Therapie.

[6]  J. Bosch,et al.  Available evidence and outcome of off-label use of rituximab in clinical practice , 2013, European Journal of Clinical Pharmacology.

[7]  Christine Y. Lu,et al.  Access to high cost drugs in Australia , 2004, BMJ : British Medical Journal.

[8]  G. Gallego,et al.  Impact of High‐Cost Drugs for Individual Patient Use , 2004 .

[9]  R. Day,et al.  Drug and therapeutics committees — are they fulfilling their potential to improve the quality use of medicines? , 2003 .

[10]  J. Green,et al.  Evaluating a restrictive formulary system by assessing nonformulary-drug requests. , 1985, American journal of hospital pharmacy.

[11]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.